Home › Pituitary Tumors › NCT07456878
Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas
RecruitingPhase 1
Who can join
Ages 18 to 75 · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients 18 to 75 years of age with biochemically proven CD, Acromegaly, or tumor hyperprolactinemia as per current Endocrinology guidelines. * Clinical DCE-MRI protocol that is negative or equivocal for identifiable tumor. * Patient willing to have surgery if lesion found, or already scheduled for surgery and lesion identification would be helpful. * Able to provide informed consent and be capable of completing the imaging protocols. * Female subjects of childbearing potential (women of childbearing potential \[WOCBP\]) must have a negative urine pregnancy test ≤48 hours prior to the 18F-FET injection. Exclusion Criteria: * Patients with contraindications to MRI or PET scans. * Patients with known allergies to contrast agents or other imaging-related materials. * Patients with severe medical conditions that preclude participation in the study (e.g. inability to lie supine for 30-60 minutes). * Patients with successful MRI localization of the adenoma.
About the study
The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI in detecting MRI-occult primary or residual/recurrent functional pituitary adenomas (PAs) and its influence on clinical and surgical decisions.
What is being tested
- FET-PET/MRI (drug)
Sponsor: Mayo Clinic · Participants: 5 · Started: Jan 8, 2026
Contact the study team
- Julia Santos · Phone: 904-953-3280
Official record on ClinicalTrials.gov — NCT07456878
Locations in the U.S.
| Florida | Mayo Clinic, Jacksonville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.